Evaluating the efficacy of placental-derived allograft in managing non-healing pressure ulcers
DOI:
https://doi.org/10.63676/1bzgbv82Keywords:
diabetic foot ulcer, chronic wounds, tissue regeneration, clinical trial designAbstract
Background: Chronic wounds such as pressure ulcers (PUs) cause physical, emotional and financial strain on patients. Amniotic membranes have been demonstrated in previous studies to aid wound closure.
Methods: This study aims to examine the efficacy of cellular, acellular, and matrix-like products (CAMPs) in achieving complete closure of PUs that were not responsive to standard of care (SOC) treatment.
Results: Overall, 25 subjects with 37 pressure ulcers that had failed to heal with 6 weeks of SOC were treated with three-layer placental derived allograft (TLPA) for up to 16 weeks. Mean age was 69.3 years, 16 patients were female, and 9 were male. At baseline prior to intervention, mean wound size was 44.9cm2 (SD 103.5) and three (8.1%) PUs achieved 40% or greater percent area reduction (PAR). At the end of TLPA treatment, 33 (89.2%) of PUs had a PAR of 40% or greater.
Conclusion: TLPA treatment was shown to achieve 40% or more wound area reduction in this cohort of 25 subjects with 37 PUs that had not responded to SPC. The observed rate of improvement supports further investigation of TLPA in prospective controlled studies to validate efficacy, assess time to closure, and determine cost-effectiveness for PUs.
References
Zhang S, Wei G, Han L et al. Global, regional and national burden of decubitus ulcers in 204 countries and territories from 1990 to 2021: a systematic analysis based on the global burden of disease study 2021. Front Public Health. 2025; 13:1494229. https://doi.org/10.3389/fpubh.2025.1494229
Jaul E, Barron J, Rosenzweig JP et al. An overview of co-morbidities and the development of pressure ulcers among older adults. BMC Geriatr. 2018; 18, 305. https://doi.org/10.1186/s12877-018-0997-7
Wu, Stephanie et al. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). J Wound Care. 2023; 32,Sup4b: S1-S31. https://doi.org/10.12968/jowc.2023.32.Sup4b.S1
Dehghani M, Azarpira N, Karimi VM, Mossayebi H, Esfandiari E. Grafting with cryopreserved amniotic membrane versus conservative wound care in treatment of pressure ulcers: a randomized clinical trial. Bull Emerg Trauma. 2017; 5(4), 249–258. https://doi.org/10.18869/ACADPUB.BEAT.5.4.452
Lakmal K, Basnayake O, Hettiarachchi D. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg. 2021;21(1):87. https://doi.org/10.1186/s12893-021-01084-8
Tettelbach WH, Armstrong DG, Chang TJ, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022;31(Sup2):S10-S31. https://doi.org/10.12968/jowc.2022.31.Sup2.S10
Tettelbach W, Armstrong D, Niezgoda J, et al. The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination. J Wound Care. 2025;34(Sup5):S5-S14. https://doi.org/10.12968/jowc.2025.0120
Downloads
Published
Data Availability Statement
The data is proprietary but is available on request to the corresponding author.
Issue
Section
License
Copyright (c) 2025 International Journal of Tissue Repair
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
